Veeda Clinical Research Acquires European CRO – Heads – Expanding Global Reach & Capabilities

27 March 2024
veeda_logo_large
  • Heads (Health Data Specialists) is a full-service Global Contract Research Organization (CRO) dedicated to the conduct of clinical studies, with expertise in oncology studies.
  • Veeda Clinical Research, together with its subsidiary Bioneeds, offers a comprehensive portfolio of clinical, preclinical and bio-analytical services to support innovator, biosimilar and generic drug development programs of global clients.
  • Heads gain access to the Indian and South-East Asian markets, offering access of patient population to its clients.
  • Veeda expands its reach to major geographies and adds capabilities of late-stage clinical trial execution with strong focus on Oncology.

Dublin (Ireland)/Ahmedabad (India), March 27, 2024: Veeda Clinical Research Limited, a full-service contract research organization (CRO) with a proven record of drug development success, announced that it has acquired Heads, a privately held European CRO, which specializes in conducting clinical trials in oncology. Established in 2010, Heads has operational presence in 25 multiple strategically important locations across Europe, North America and Asia Pacific region. Through this acquisition, Veeda enters the league of global CROs with integrated capabilities to extend contract research services from discovery to clinical development extending to post commercial launch.

The acquisition provides Heads a strong operational platform and an opportunity to expand its expertise and capabilities to the Indian and South-East Asian markets. India's diverse demographic profile provides a unique opportunity to conduct clinical trials, especially in therapeutic areas including oncology, diabetes, hypertension, infectious diseases, and special diseases.

With this acquisition, Veeda’s global pharmaceutical and biotech clients can now leverage the unique and unparalleled suite of early to late-phase CRO services across Europe, US, and Asia Pacific. Veeda’s ever-growing relationship with large biopharma companies and access to KOL’s across multiple countries will accelerate execution of global clinical trials in both the western and eastern populations. In recent years, Veeda has added expertise in the late stage clinical and global trials for large molecules. High quality and efficient clinical trial execution remains the top priority for the clients of the combined entity.

mahesh-profile-photo_feb23-tpl.jpg

Sharing details related to common synergies between Veeda and Heads, Dr. Mahesh Bhalgat (pictured above), Group – CEO of Veeda Clinical Research, said, “With the growing emphasis on global clinical trials, this acquisition now positions Veeda to offer access to a very diverse population for conducting large scale multi-geography trials efficiently. Both organizations are focused towards driving equitable access to trials and fostering the development of innovative treatments worldwide. The acquisition brings together a unique team of scientists and researchers, having deep therapeutic area expertise in the Oncology research. This equips Veeda to build long and enduring site relationships across geographies.” 

Elaborating on the prospects of this partnership, Mr. Binoy Gardi (below), Executive Vice Chairperson of Veeda Clinical Research, said, “As we integrate the operations of both the companies, this is an exciting opportunity for Veeda and Heads to expand markets, leverage complimentary capabilities and add value to our clients. We believe that our combined strengths will enable us to drive greater efficiency, innovation, and excellence in delivering research outcomes for drug development programs of our clients worldwide.”

mr_binoy_gardi-tpl.jpg

“There is a very strong cultural fit between Heads and Veeda,“ said Dr. George Kouvatseas (below), Partner, Heads. “Both companies share a dedication to scientific leadership, expansion of highly specialized services to meet the emerging needs of our clients, an uncompromising focus on quality, and a belief that our strength is in our people and the way in which they work together.

“During the integration phase, Heads will continue to offer uninterrupted support to client programs. The Veeda and Heads organization together are committed to nimble operations through a structured integration process without impact to ongoing client programs.”

g-kouvatseas-photo-tpl.jpg

About Veeda Clinical Research Limited:
Veeda Clinical Research Limited (“Veeda”) is one of the largest independent, full-service clinical research organizations, headquartered in Ahmedabad, India. Veeda offers a range of bioequivalence studies and early and late phase clinical trials. Veeda has successfully completed several regulatory inspections and is approved by USFDA, UK MHRA, ANVISA (Brazil), and WHO. Veeda has experience in conducting complex clinical studies. Visit https://www.veedacr.com/

About Heads:
Heads is a full-service Global Contract Research Organization (CRO) dedicated to the conduct of clinical studies, with expertise in haemato-oncology studies. It provides complete range of
clinical trial services, from start-up to completion, from Phase I to IV. In addition, it offers strategic oncology drug development consulting and expert advice, as the team understands
the challenges of developing anti-cancer drugs in the complex, highly competitive and rapidly developing oncology market. Visit https://heads-research.com/

For more information:

Siddharth Baad, Corporate Communications

siddharth.b2274@veedacr.com

+91-6351332609

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical